Black Diamond Therapeutics, Inc.
BDTX
$1.60
$0.010.63%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -45.51% | -33.62% | 39.20% | -1.57% | -23.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.49% | -24.50% | 10.47% | -6.10% | -4.56% |
| Operating Income | 26.49% | 24.50% | -10.47% | 6.10% | 4.56% |
| Income Before Tax | 17.64% | 32.38% | -3.95% | 12.69% | 7.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.64% | 32.38% | -3.95% | 12.69% | 7.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.64% | 32.38% | -3.95% | 12.69% | 7.92% |
| EBIT | 26.49% | 24.50% | -10.47% | 6.10% | 4.56% |
| EBITDA | 26.60% | 24.49% | -10.67% | 5.97% | 4.40% |
| EPS Basic | 24.87% | 39.04% | 31.17% | 38.52% | 35.10% |
| Normalized Basic EPS | 37.88% | 39.04% | 31.18% | 35.03% | 38.67% |
| EPS Diluted | 24.87% | 39.04% | 31.17% | 38.52% | 35.10% |
| Normalized Diluted EPS | 37.88% | 39.04% | 31.18% | 35.03% | 38.67% |
| Average Basic Shares Outstanding | 9.63% | 10.92% | 51.04% | 42.00% | 41.90% |
| Average Diluted Shares Outstanding | 9.63% | 10.92% | 51.04% | 42.00% | 41.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |